Bioregenx BRGX
OTC BRGX
$0.00 +0.00 (+0.00%)
At close: Oct 14, 2026 · 4:00 PM EDT

Bioregenx, Inc. (BRGX) Long-Term Debt Repayments (2022 - 2026)

Updated

Bioregenx (BRGX) posted Long-Term Debt Repayments of $56,017 for Q1 2026, up 437.8% from $10,415 a year earlier and up 26.9% from the prior quarter.

Analysis

Bioregenx, Inc. (BRGX) Long-Term Debt Repayments (2022 - 2026) Analysis & Trends

For the trailing twelve months through Mar 31, 2026, Long-Term Debt Repayments at Bioregenx was $160,010, up 288.2% year-over-year; for FY2025, it came in at $114,408, up 137.2% from FY2024.

  • Annual Long-Term Debt Repayments shows a three-year compound annual growth rate of 446.7% (FY2022 to FY2025).
  • In prior years, Bioregenx's Long-Term Debt Repayments was $48,240 in FY2024 (-74.7%), $191,001 in FY2023 and $700.00 in FY2022.
  • The Q1 2026 figure stands as the highest quarterly Long-Term Debt Repayments since Q4 2023.
  • On a year-over-year basis, Long-Term Debt Repayments has increased in each of the last four quarters, with growth averaging 180.9% over the last six quarters.
  • According to Business Quant data, Long-Term Debt Repayments for the three prior quarters was $44,142 (Q4 2025), $46,674 (Q3 2025) and $13,177 (Q2 2025).
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 56,017.00
Dec 31, 2025 44,142.00
Sep 30, 2025 46,674.00
Jun 30, 2025 13,177.00
Mar 31, 2025 10,415.00
Dec 31, 2024 8,470.00
Sep 30, 2024 10,312.00
Jun 30, 2024 12,020.00
Mar 31, 2024 17,438.00
Dec 31, 2023 211,562.00
Jun 30, 2023 -172,890.00
Mar 31, 2023 173,000.00
Dec 31, 2022 700.00
API Access

Bioregenx, Inc. Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=BRGX&period=max&api_key=YOUR_API_KEY